Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Open-Label, Multicenter Study Examining the Effects of Duration of Treatment of PEGASYS® in Combination With Daily COPEGUS® + Amantadine in Patients With Chronic HCV After Relapse to Previous (Peg)IFN + Ribavirin Therapy.

NCT00299923 is registered in ClinicalTrials.gov with University of Hamburg-Eppendorf as lead sponsor.

NCT NCT00299923
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00299923 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Open-Label, Multicenter Study Examining the Effects of Duration of Treatment of PEGASYS® in Combination With Daily COPEGUS® + Amantadine in Patients With Chronic HCV After Relapse to Previous (Peg)IFN + Ribavirin Therapy.
Lead sponsor
University of Hamburg-Eppendorf
Phase
Phase 3
Overall status
Unknown status
Start date
November 30, 2005
Completion date
Not reported
Enrollment
300
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis c, chronic, relapse